Literature summary for 2.7.1.74 extracted from

Ohhashi, S.; Ohuchida, K.; Mizumoto, K.; Fujita, H.; Egami, T.; Yu, J.; Toma, H.; Sadatomi, S.; Nagai, E.; Tanaka, M.
Down-regulation of deoxycytidine kinase enhances acquired resistance to gemcitabine in pancreatic cancer (2008), Anticancer Res., 28, 2205-2212.

Search for more literature for 2.7.1.74

Application

Application	Comment	Organism
medicine	in gemcitabine-resistant pancreatic cancer cells, expression of deoxycytidine kinase is significantly reduced compared with that of parental cells. Treatment with siRNA targeted to deoxycytidine kinase reduces gemcitabine sensitivity without affecting cell proliferation. Downregulation of gemcitabine-related genes RRM1 and RRM2 by siRNA increases gemcitabine sensitivity and reduces cell proliferation even without gemcitabine treatment	Homo sapiens

Protein Variants

Protein Variants	Comment	Organism
additional information	in gemcitabine-resistant pancreatic cancer cells, expression of deoxycytidine kinase is significantly reduced compared with that of parental cells. Treatment with siRNA targeted to deoxycytidine kinase reduces gemcitabine sensitivity without affecting cell proliferation. Downregulation of gemcitabine-related genes RRM1 and RRM2 by siRNA increases gemcitabine sensitivity and reduces cell proliferation even without gemcitabine treatment	Homo sapiens

Organism

Organism	UniProt	Comment	Textmining
Homo sapiens	-	patients with pancreatic cancer	-

Source Tissue

Source Tissue	Comment	Organism	Textmining
pancreas	gemcitabine-resistant pancreatic cancer cell	Homo sapiens	-

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)